TCBP Trading Continues Unabated on Nasdaq Stock Exchange
TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other conditions, has announced the continuous trading of its American Depository Shares (ADSs) on the Nasdaq Global Select Market under the ticker symbol 'TCBP'. The company confirmed there has been no interruption in trading, and shares are expected to continue trading without disruption.
TC BioPharm (NASDAQ: TCBP), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie allogeniche con cellule T gamma-delta per il cancro e altre condizioni, ha annunciato la continua negoziazione delle sue Azioni di Deposito Americane (ADS) sul Nasdaq Global Select Market con il simbolo ticker 'TCBP'. L'azienda ha confermato che non ci sono state interruzioni nella negoziazione e le azioni sono previste per continuare a essere scambiate senza interruzioni.
TC BioPharm (NASDAQ: TCBP), una empresa de biotecnología en etapa clínica centrada en el desarrollo de terapias con células T gamma-delta alogénicas para el cáncer y otras condiciones, ha anunciado la negociación continua de sus Acciones de Depósito Americano (ADS) en el Nasdaq Global Select Market bajo el símbolo ticker 'TCBP'. La empresa confirmó que no ha habido interrupciones en la negociación, y se espera que las acciones continúen negociándose sin interrupciones.
TC BioPharm (NASDAQ: TCBP)는 암 및 기타 질환을 위한 동종 감마-델타 T 세포 치료법 개발에 중점을 둔 임상 단계의 생명공학 회사로, 'TCBP'라는 티커 기호 아래 Nasdaq Global Select Market에서 자사의 미국 예탁주식(ADS)의 지속적인 거래를 발표했습니다. 이 회사는 거래에 중단이 없었음을 확인했으며, 주식이 계속해서 중단 없이 거래될 것으로 예상하고 있습니다.
TC BioPharm (NASDAQ: TCBP), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies par cellules T gamma-delta allogéniques pour le cancer et d'autres conditions, a annoncé la négociation continue de ses American Depository Shares (ADS) sur le Nasdaq Global Select Market sous le symbole ticker 'TCBP'. L'entreprise a confirmé qu'il n'y a eu aucune interruption dans la négociation, et les actions devraient continuer à se négocier sans interruption.
TC BioPharm (NASDAQ: TCBP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen Gamma-Delta-T-Zelltherapien für Krebs und andere Erkrankungen konzentriert, hat den kontinuierlichen Handel seiner American Depository Shares (ADS) an der Nasdaq Global Select Market unter dem Tickersymbol 'TCBP' bekannt gegeben. Das Unternehmen bestätigte, dass es keine Unterbrechungen im Handel gegeben hat und die Aktien voraussichtlich ohne Unterbrechungen weiter gehandelt werden.
- Maintained Nasdaq listing status without interruption
- None.
There has been no halt in trading and shares are expected to continue trading unabated. This press release is for informational purposes only. It shall not constitute an offer to sell or exchange nor the solicitation of an offer to buy shares of the Company's common stock or any other securities.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-trading-continues-unabated-on-nasdaq-stock-exchange-302343271.html
SOURCE TC BioPharm
FAQ
Is TCBP still trading on Nasdaq as of January 2025?
Has there been any trading halt for TCBP stock?
What type of therapy is TC BioPharm developing?
What market does TCBP trade on?
